Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference

Abstract

Selective silencing of mammalian gene expression has recently been achieved using short interfering RNA (siRNA). Synthetic siRNA targets homologous mRNA for degradation and the process is highly efficient. Here we demonstrate siRNA silencing of pathogenic viral gene expression. As a well characterized model we chose cervical carcinoma cells positive for human papillomavirus type 16. Over 90% of human cervical cancers are positive for papillomavirus and abnormal cell proliferation is driven by co-operative effects of viral E6 and E7 genes. We sought to silence HPV E6 and E7 gene expression using siRNAs to target the respective viral mRNAs. Our results indicate selective degradation of E6 and E7 mRNAs. Silencing was sustained for at least 4 days following a single dose of siRNA. E6 silencing induced accumulation of cellular p53 protein, transactivation of the cell cycle control p21 gene and reduced cell growth. In contrast, E7 silencing induced apoptotic cell death. HPV-negative cells appeared unaffected by the anti-viral siRNAs. Thus we demonstrate for the first time (i) that siRNA can induce selective silencing of exogenous viral genes in mammalian cells, and (ii) that the process of siRNA interference does not interfere with the recovery of cellular regulatory systems previously inhibited by viral gene expression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Aguilar-Lemarroy A, Gariglio P, Whitaker NJ, Eichhorst ST, zur Hausen H, Kramer PH, Rosl F . 2002 Oncogene 21: 165–175

  • Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM . 1987 J. Virology 61: 962–971

  • Butz K, Shahabeddin L, Geisen C, Spitkovsky D, Ullmann A, Hoppe-Seyler F . 1995 Oncogene 10: 927–936

  • Butz K, Geisen C, Ullmann A, Spitkovsky D, Hoppe-Seyler F . 1996 Int. J. Cancer 68: 506–513

  • Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA . 2001 Proc. Natl. Acad. Sci. USA 98: 9742–9747

  • Carthew RW . 2001 Curr. Opin. Biol. 13: 244–248

  • Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T . 2001 Nature 411: 428–429

  • Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC . 1998 Nature 391: 806–811

  • Gu W, Pan F, Zhang H, Bassell GJ, Singer RH . 2002 J. Cell Biol. 156: 41–51

  • Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M . 2001 Proc. Natl. Acad. Sci. USA 98: 1218–1223

  • Hietenan S, Lain S, Krausz E, Blattner C, Lane DL . 2000 Proc. Natl. Acad. Sci. USA 97: 8501–8506

  • Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH . 2001 Genes Dev. 15: 2654–2659

  • Knight SW, Bass BL . 2001 Science 293: 2269–2271

  • Koromilas AE, Li S, Matlashewski G . 2001 Cytokine Growth Factor Rev. 12: 157–170

  • Levine AJ . 1997 Cell 88: 323–331

  • Lipardi C, Wei Q, Paterson BM . 2001 Cell 107: 297–307

  • McMurray HR, Nguyen D, Westbrook TF, McAnce DJ . 2001 Int. J. Exp. Pathol. 82: 15–33

  • Mosner J, Mummenbrauer T, Brauer C, Sczakiel G, Grosse F, Deppert W . 1995 EMBO J. 14: 4442–4449

  • Novina CD, Murray FM, Dykxhoorn DM, Beresford PJ, Reiss J, Lee S-K, Collman RG, Lieberman J, Shankar P, Sharp PA . 2002 Nature Med. 8: 681–686

  • Nykanen A, Haley B, Zamore PD . 2001 Cell 107: 309–321

  • Orphanides G, Reinberg D . 2002 Cell 108: 439–451

  • Patel D, Huang SM, Baglia LA, McCance DJ . 1999 EMBO J. 18: 5061–5072

  • Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM . 1990 Cell 63: 1129–1136

  • Scheffner M, Münger K, Byrne JC, Howley PM . 1991 Proc. Natl. Acad. Sci. USA 88: 5523–5527

  • Scheffner M, Huibregtse JM, Vierstra RD, Howley PM . 1993 Cell 75: 495–505

  • Sharp PA . 2001 Genes Dev. 15: 485–490

  • Steele C, Cowsert LM, Shillitoe EJ . 1993 Cancer Res. 53: 2330–2337

  • Thomas M, Pim D, Banks L . 1999 Oncogene 18: 7690–7700

  • Zamore PD, Tuschl T, Sharp PA, Bartel DP . 2000 Cell 101: 25–33

  • zur Hausen H . 2000 J. Natl. Cancer Inst. 92: 690–698

Download references

Acknowledgements

We thank Professor Tim Skerry (Royal Veterinary College, London) and Dr Su Metcalfe (Department of Surgery, University of Cambridge) for critical reading of the manuscript. This work was funded by a programme grant from Yorkshire Cancer Research to J Milner.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jo Milner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jiang, M., Milner, J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21, 6041–6048 (2002). https://doi.org/10.1038/sj.onc.1205878

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205878

Keywords

This article is cited by

Search

Quick links